3M, a multinational corporation, is nearing the end of the largest mass tort litigation in U.S. history, with a settlement of approximately $6.01 billion. This settlement involves around 250,000 plaintiffs, mainly military veterans and service members, who alleged that 3M manufactured defective earplugs that caused hearing loss. The court-appointed lead plaintiffs’ counsel, Bryan Aylstock, expressed confidence that this substantial settlement would not only hold 3M accountable but also provide just compensation to the veterans affected by the defective earplugs.
While the settlement in the earplug lawsuit brings some relief to 3M, the company still faces other costly legal troubles. One significant legal challenge is the approval of a $10.3 billion settlement with water utilities over drinking water contamination caused by “forever chemicals.” While this settlement has faced opposition from more than 20 states, it only covers a subset of liabilities and does not include a growing number of states that have sued 3M. Additionally, personal injury claims are not part of this settlement.
Moreover, Capstone estimates that 3M’s total liability risk from PFAS (per- and polyfluoroalkyl substances) amounts to nearly $30 billion, exceeding the current settlements. The company has also encountered lawsuits from countries such as the Netherlands and Belgium regarding PFAS contamination. The potential ban on PFAS chemicals in Europe and the consideration of labeling PFAS as a hazardous chemical by the U.S. Environmental Protection Agency indicate the increasing scrutiny of this toxic chemical.
In order to fund the settlements and manage its financial situation, 3M has implemented cost-cutting measures, including the elimination of 8,500 jobs, which amounts to 10% of its workforce, in the current year. Additionally, the industrial giant plans to spin off its successful health-care business by late 2023 or early 2024. Analysts predict that this transaction could generate $7 billion to $9 billion in cash flows for 3M.
Much debate surrounds 3M’s dividend, which currently offers a 6.1% yield to investors. Wall Street firms such as JPMorgan, UBS, and RBC have expressed concerns about the sustainability of 3M’s dividend. UBS analysts stated that they expect the dividend to be lowered following the spin-out of the company’s health-care unit. The outcome of this dividend debate remains uncertain.
3M is currently experiencing leadership changes, with the appointment of Bryan Hanson, the CEO of Zimmer Biomet, as the CEO of its health-care business. This transition seems to be on track, as the company announced this development recently. Additionally, 3M’s current Chief Financial Officer, Monish Patolawala, has also been named President, positioning him as a potential successor to CEO Mike Roman. Roman has been leading 3M for the past five years, navigating the challenges of the Covid-19 pandemic, the earplug and PFAS litigations, and shareholder criticism concerning the underperformance of the company’s stock.
Since Roman’s appointment as CEO in 2018, 3M’s stock has experienced a significant decline of 48%. In contrast, the XLI Industrials ETF has rallied by 50% during the same period. However, on the day of the settlement announcement, 3M’s stock rose by more than 1%.
While 3M has reached a monumental settlement in the earplug lawsuit, legal troubles persist for the company. The approval of the water utilities settlement and the potential impact of PFAS litigation and regulatory actions pose significant challenges for 3M. The company’s cost-cutting measures, including job reductions and the planned spin-off of its health-care business, aim to mitigate financial strain. Additionally, the sustainability of 3M’s dividend and the leadership changes within the company add further complexity to its future prospects. All eyes will be on 3M as it navigates through these legal and financial headwinds.
Leave a Reply